Global Cancer Stem Cell Therapy Market Outlook 2020 - Competitive Landscape Report - Research and Markets - Seite 2

Development of targeted drugs is going to play an important role in development in counteracting cancer stem cell therapy. These drugs are expected to have high specificity due to which normal cells will be spared during treatment. They will prevent the cancerous cells to develop resistance so that they won't become recalcitrant. It will also prevent the development of new cancerous cells in the body. By preventing metastasis, spread of cancer cells in different body parts would be checked. Investigators are developing drug discovery systems which would be able to find new lead molecules for developing cancer stem cell therapies. Only few candidate molecules are able to effectively eliminate cancer stem cells. As a result, significant time is consumed in the development of cancer stem cell therapies.

Key Topics Covered:

1. Introduction to Stem Cells

2. Classification of Stem Cells
2.1 Basis of Ability to Differentiate
2.2 Basis of Origin
2.3 Basis of their Source

3. Stem Cell Transplants Classification
3.1 Autologous Stem Cell Transplants
3.2 Allogeneic Stem Cell Transplants
3.3 Syngeneic Stem Cell Transplants

4. Cancer Stem Cell Therapy Mechanism of Action
4.1 Targeting Signaling Pathways
4.1.1 Hedgehog Signaling Pathway
4.1.2 Notch Signaling Pathway
4.1.3 WNT Signaling Pathway
4.2 Targeting Cell Surface Markers
4.3 Targeting miRNA Expression

5. Global Cancer Stem Cell Market Analysis
5.1 Current Market Scenario
5.2 Global Cancer Stem Cell Therapies Pipeline Overview

6. Global Cancer Stem Cell Market Dynamics
6.1 Favorable Market Parameters
6.2 Commercialization Challenges

7. Global Cancer Stem Cell Market Future Outlook

8. Global Cancer Stem Cell Clinical Pipeline by Company & Phase
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-I
8.5 Phase-I/II
8.6 Phase-II
8.7 Phase-III

9. Discontinued & No Development of Cancer Stem Cell in Clinical Pipeline by Company & Phase
9.1 Discontinued
9.2 No Development Reported

10. Competitive Landscape
10.1 Aldagen
10.2 Apceth
10.3 Benitec Biopharma
10.4 Celgene Corporation
10.5 Cellonis Biotechnologies
10.6 Caladrius Biosciences
10.7 Commence Bio
10.8 ExCellThera
10.9 Galena Biopharma
10.10 Gamida Cell
10.11 Genexine
10.12 ImmunoCellular Therapeutics
10.13 K-STEMCELL
10.14 Medipost
10.15 Mesoblast
10.16 Novartis
10.17 Nuo Therapeutics
10.18 OncoCyte Corporation
10.19 Pluristem Therapeutics
10.20 ReNeuron
10.21 Sangamo BioSciences
10.22 Takeda
10.23 Vericel Corporation

For more information visit http://www.researchandmarkets.com/research/kv65vn/global_cancer

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]